Comparative Pharmacology
Head-to-head clinical analysis: FULVICIN P G 165 versus ORAVIG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FULVICIN P G 165 versus ORAVIG.
FULVICIN P/G 165 vs ORAVIG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Griseofulvin binds to and disrupts microtubule function by inhibiting spindle formation and mitosis in dermatophytes, leading to inhibition of fungal cell division.
Miconazole, an azole antifungal, inhibits fungal cytochrome P450 14α-demethylase, thereby blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
165 mg orally once daily.
ORAVIG (miconazole) 50 mg buccal tablet applied once daily to the upper gum region (canine fossa) for 14 consecutive days. The tablet is placed with the rounded side against the gum and held in place for 30 seconds to ensure adhesion.
None Documented
None Documented
Terminal elimination half-life is approximately 9-24 hours; dependent on formulation and absorption rate. Steady-state achieved within 4-5 days.
Terminal elimination half-life is approximately 24 hours, supporting once-daily buccal administration for sustained local oropharyngeal concentrations.
Primarily renal excretion of metabolites; <1% excreted unchanged. Biliary/fecal elimination accounts for ~30% of metabolites.
Primarily fecal (approximately 52%) with 39% of the dose recovered in urine; less than 0.5% of the dose is excreted unchanged in urine.
Category C
Category C
Antifungal
Antifungal